Nuclear matrix proteins and their potential applications to diagnostic pathology

American Journal of Clinical Pathology

Volumn 111, Issue 2, 1999, Pages 267-274

  Hughes, Jonathan H ^a   Cohen, Michael B ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Apoptosis; Nuclear matrix proteins; Prognostic factors; Tumor markers

Indexed keywords

BIOCHEMICAL MARKER; MATRIX PROTEIN;

APOPTOSIS; CANCER DIAGNOSIS; CELL NUCLEUS; CELL NUCLEUS MATRIX; CHROMATIN STRUCTURE; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG TARGETING; HUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0032900169     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/111.2.267     Document Type: Review

References (44)

1. Berezney R, Mortillaro MJ, Wei X, et al. The nuclear matrix: a structural milieu for genomic function. Int Rev Cytol. 1995;162A:1-65.
2. Keesee SK, Briggman JV, Thill G, et al. Utilization of nuclear matrix proteins fur cancer diagnosis. Crit Rev Eukaryot Gene Expr. 1996;6:189-214.
3. Fernandes DJ, Catapano CV. The nuclear matrix as a site of anticancer drug action. Int Rev Cytol. 1995;162A:539-576.
4. Replogle-Schwab R, Pienta KJ, Getzenberg RH. The utilization of nuclear matrix proteins for cancer diagnosis. Crit Rev Eukaryot Gene Expr. 1996;6:103-113.
5. Pienta KJ, Lehr JE. A common set of nuclear matrix proteins in prostate cancer cells. Prostate. 1993;23:61-67.
6. Miller T, Beausang LA, Meneghini M, et al. Death-induced changes to the nuclear matrix: the use of anti-nuclear matrix antibodies to study agents of apoptosis. Biotechniques. 1993;15:1042-1047.
7. Zweyer M, Riederer BM, Ochs RL, et al. Association of nuclear matrix proteins with granular and threaded nuclear bodies in cell lines undergoing apoptosis. Exp Cell Res. 1997;230:325-336.
8. Martelli AM, Bareggi R, Bortul R, et al. The nuclear matrix and apoptosis. Histochem Cell Biol. 1997;108:1-10.
9. Arends MJ, Morris RG, Wyllie AH. Apoptosis: the role of the endonuclease. Am J Pathol. 1990;136:593-608.
10. Ruh MF, Dunn R H, Ruh TS. Interrelationships between nuclear structure and ligand-activated intracellular receptors. Crit Rev Eukaryot Gene Expr. 1996;6:271-283.
11. Mattem KA, van Goethem RE, de Jong L, et al. Major internal nuclear matrix proteins are common to different human cell types. J Cell Biochem. 1997;65:42-52.
12. Bidwell JP, Fey EG, van Wijnen AJ, et al. Nuclear matrix proteins distinguish normal diploid osteoblasts from osteosarcoma cells. Cancer Res. 1994;54:28-32.
13. Alvarez M, Long H, Onyia J, et al. Rat osteoblast and osteosarcoma nuclear matrix proteins hind with sequence specificity to the rat type I collagen promoter. Endocrinology. 1997;138:482-489.
14. Barboro P, Alberti I, Sanna P, et al. Changes in the cytoskeletal and nuclear matrix proteins in rat hepatocyte neoplastic nodules in their relation to the process of transformation. Exp Cell Res. 1996;225:315-327.
15. Bidwell JP, Fey EG, Marks SC Jr. Nuclear matrix-intermediate filament proteins of the dental follicle/enamel epithelium and their changes during tooth eruption in dogs. Arch Oral Biol. 1995;40:1047-1051.
16. Samuel SK, Minish TM, Davie JR. Altered nuclear matrix profiles in oncogene-transformed mouse fibroblasts exhibiting high metastatic potential. Cancer Res. 1997;57:147-151.
17. Getzenberg RH, Pienta KJ, Huang EY, et al. Identification of nuclear matrix proteins in the cancer and normal rat prostate. Cancer Res. 1991;51:6514-6520.
18. Partin AW, Getzenberg RH, CarMichael MJ, et al. Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Res. 1993;53:744-746.
19. Keesee SK, Meneghini MD, Szaro RP, et al. Nuclear matrix proteins in human colon cancer. Proc Natl Acad Sci U S A. 1994;91:1913-1916.
20. Cahill DP, Lengauer C, Yu J, et al. Mutations of mitotic checkpoint genes in human cancers. Nature. 1998;392:300-303.
21. Khanuja PS, Lehr JE, Soule HD, et al. Nuclear matrix proteins in normal and breast cancer cells. Cancer Res. 1993;53:3394-3398.
22. Fey EG, Penman S. Nuclear matrix proteins reflect cell type of origin in cultured human cells. Proc Natl Acad Sci U S A. 1988;85:121-125.
23. Weidner N, Weinberg DS, Hardy SC. Localization of nuclear matrix proteins (NMPs) in multiple tissue types with NM-200.4 (an antibody strongly reactive with NMPs found in breast carcinoma). Am J Pathol. 1991;138:1293-1298.
24. Wisecarver JL, Synovec MS, Pirrucello S, et al. Marking characteristics of anti-nuclear matrix protein NM200.4 in human breast carcinomas and normal human tissues. J Clin Lab Anal. 1993;7:134-138.
25. Samuel SK, Minish TM, Davie JR. Nuclear matrix proteins in well and poorly differentiated human breast cancer cell lines. J Cell Biochem. 1997;66:9-15.
26. Donat TL, Sakr W, Lehr JE, et al. Unique nuclear matrix protein alterations in head and neck squamous cell carcinomas: intermediate biomarker candidates. Otolaryngol Head Neck Surg. 1996;114:387-393.
27. McCaffery JD, Gapany M, Faust RA, et al. Nuclear matrix proteins as malignant markers in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1997;123:283-288.
28. Yam HF, Chew EC, Yang L, et al. Human papillomavirus type 16 DNA integration in nuclear matrix and chromosome scaffold associated DNA in a cervical carcinoma cell line. Oncol Rep. 1995;2:1093-1096.
29. Yang L, Yam HF, Cheng-Chew SB, et al. The association of HPV 16 DNA with specific nuclear matrix proteins of normal and cervical carcinoma cell. Anticancer Res. 1997;17:343-347.
30. Shelfo SW, Soloway MS. The role of nuclear matrix protein 22 in the detection of persistent or recurrent transitional-cell cancer of the bladder. World J Urol. 1997;15:107-111.
31. Getzenberg RH, Konety BR, Oeler TA, et al. Bladder cancer-associated nuclear matrix proteins. Cancer Res. 1996;56:1690-1694.
32. Chen YT, Hayden CL, Marchand KJ, et al. Comparison of urine collection methods for evaluating urinary nuclear matrix protein, NMP22, as a tumor marker. J Urol. 1997;158:1899-1901.
33. Carpinito GA, Stadler WM, Briggman JV, et al. Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol. 1996;156:1280-1285.
34. Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, et al. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol. 1998;159:394-398.
35. Soloway MS, Briggman V, Carpinito GA, et al. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol. 1996;156:363-367.
36. Gordon JN, Shu WP, Schlussel RN, et al. Altered extracellular matrices influence cellular processes and nuclear matrix organizations of overlying human bladder urothelial cells. Cancer Res. 1993;53:4971-4977.
37. Compton DA, Cleveland DW. NuMA is required for the proper completion of mitosis. J Cell Biol. 1993;120:947-957.
38. Yang CH, Lambie EJ, Snyder M. NuMA: an unusually long coiled-coil related protein in the mammalian nucleus. J Cell Biol. 1992;116:1303-1317.
39. Bidwell J, Van Wijnen A, Banerjee C, et al. Parathyroid-responsive modifications in the nuclear matrix of ROS 17/2.8 rat osteosarcoma cells. Endocrinology. 1994;134:1738-1744.
40. Bidwell J, Feister H, Swartz D, et al. Parathyroid hormone regulates the expression of rat osteoblast and osteosarcoma nuclear matrix proteins. J Cell Biochem. 1996;63:374-383.
41. Bidwell JP, van Wijnen AJ, Fey EG, et al. Osteocalcin gene promoter-binding factors are tissue-specific nuclear matrix components. Proc Natl Acad Sci U S A. 1993;90:3162-3166.
42. Cataldi A, Antonucci A, Robuffo I, et al. Rapid and transient phosphorylation of nuclear matrix proteins upon interferon-alpha treatment in Daudi lymphoma cells. J Interferon Cytokine Res. 1995;15:461-465.
43. Miller TE, Beausang LA, Winchell LF, et al. Detection of nuclear matrix proteins in serum from cancer patients. Cancer Res. 1992;52:422-427.
44. Dynlacht JR, Henthorn J, O'Nan C, et al. Flow cytometric analysis of nuclear matrix proteins: method and potential applications. Cytometry. 1996;24:348-359.